At a Glance
- Companies: Wave Life Sciences; GSK
- Location: Cambridge, MA
- Main headline: Mutual agreement; GSK collaboration continues on other programmes
- Focus area: WVE-006 RNA editing oligonucleotide for AATD
- Next steps: Wave seeks FDA accelerated approval feedback mid-2026; phase 1/2 data Q1 2026
What happened?
GSK has returned full global rights to Wave Life Sciences’ WVE-006, the most advanced RNA editing therapy for alpha-1 antitrypsin deficiency (AATD), announced on 3 February 2026. Originally licensed under a 2022 broad collaboration, GSK handed back the asset by mutual agreement, recognising Wave’s ability to advance it more rapidly.
Why does it matter?
AATD affects ~200,000 ZZ patients in US/Europe with limited options (weekly IV augmentation for lungs only; no liver therapy); WVE-006’s PRISM/AIMer editing corrects SERPINA1 Z allele transcripts, potentially offering a “functional cure” for lung/liver disease. Return de-risks Wave’s pipeline control amid positive early data.
Who’s behind it?
Wave Life Sciences leverages PRISM platform for GalNAc-conjugated RNA editing; GSK retains collaboration on up to 8 other programmes (4th selected Jan 2026), eligible for $2.8bn milestones/royalties for Wave.
How was it achieved?
RestorAATion-2 phase 1b trial (multi‑dose cohorts) showed WVE-006 editing mutant transcripts to wild‑type, with durable effects; data from 400mg multidose Q1 2026, 600mg later 2026. GSK focuses on broader respiratory assets.
What’s next?
Wave engages FDA on accelerated approval (mid-2026 feedback); cash funds ops to Q3 2028. Seeks partners while advancing obesity programmes (WVE-007 phase 2a H1 2026).
What are people saying?
Wave CEO Paul Bolno: “AATD… largest rare diseases… limited options.” Analysts: GSK’s return validates Wave’s execution for orphan asset.